Mustafa Kemal Yeniay

Mustafa Kemal Yeniay

Auto-generated profile, based on publicly available information

Mustafa Kemal Yeniay

Division of Hematology, İzmir City Hospital, İzmir 35530, Türkiye

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Istanbul Medical Journal
Verified
Journal Article
Closed access
AGAhmet Gürdal
Ahmet Gürdal
MYMustafa Kemal Yeniay
Mustafa Kemal Yeniay
ŞÇŞükrü Çetin
Şükrü Çetin
KKKadriye Kılıçkesmez
Kadriye Kılıçkesmez

12 August 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ABASLI BOZDEMİR
ASLI BOZDEMİR
SHSibel Hacioglu
Sibel Hacioglu
GCGulsum Akgun Cagliyan
Gulsum Akgun Cagliyan
NANevin Alayvaz Alayvaz Aslan
Nevin Alayvaz Alayvaz Aslan
SUSÜLEYMAN UTKU UZUN
SÜLEYMAN UTKU UZUN
NGNil Güler
Nil Güler
Background: Elranatamab, a bispecific antibody targeting BCMA and CD3, has demonstrated clinical activity in relapsed/refractory multiple myeloma. Real-world evidence regarding infectious complications and supportive care remains limited. We evaluated the early clinical activity, safety profile, infectious complications, and supportive care practices associated with relapsed/refractory multiple myeloma (RRMM). This study represents one of the first multicenter real-world evaluations of elranatamab in Türkiye. Methods: This multicenter retrospective study included 87 patients with relapsed/refractory multiple myeloma treated with elranatamab. Clinical characteristics, treatment responses, immune-mediated toxicities, infectious complications, and supportive care practices were assessed. Overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) were evaluated. Multivariable analyses were performed to identify factors associated with treatment response and clinical outcomes. Results: At 3 months, ORR was 47.1% in the ITT population, 54.7% in the mITT population, and 83.7% among evaluable patients; corresponding 6-month ORRs were 31.0%, 42.2%, and 81.8%, respectively. The high proportion of patients without landmark response assessments primarily reflected insufficient follow-up, early death, or disease progression. Elevated LDH remained independently associated with lower response probability and inferior clinical outcomes. Cytokine release syndrome (CRS) occurred in 69% of patients, with grade ≥ 3 events in 5.7%, whereas immune effector cell-associated neurotoxicity syndrome (ICANS) was infrequent (4.6%) and no grade ≥ 3 events occurred. Grade ≥ 3 infections occurred in 39% of patients, including CMV events requiring antiviral treatment in 24.1%. No HBV reactivation occurred among patients receiving antiviral prophylaxis. Median PFS and OS were 8.1 and 10.6 months, respectively. Conclusions: Elranatamab demonstrated early clinical activity and a manageable safety profile in a heavily pretreated real-world RRMM population. Infectious complications, including CMV events, remained clinically relevant, emphasizing the importance of supportive care. Longer follow-up is needed to characterize long-term outcomes.

15 August 2026 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
MBMeral Beksac
Meral Beksac
MMMetban Mastanzade
Metban Mastanzade
BDBasak Bostankolu Degirmenci
Basak Bostankolu Degirmenci
BOBeyza Oluk
Beyza Oluk
BSBuğra Sağlam
Buğra Sağlam
GSGuldane Cengiz Seval
Guldane Cengiz Seval